ESC Professional Premium Access

State-of-the-art lecture on novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Congress Presentation

About the speaker

Doctor Carolyn Ho

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)
7 presentations
2 followers

4 more presentations in this session

Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study

Speaker: Doctor P. Garcia-Pavia (Majadahonda, ES)

Thumbnail

Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy: insights from SEQUOIA-HCM

Speaker: Doctor C. Coats (Glasgow, GB)

Thumbnail

Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with an HCM sarcomeric gene mutation

Speaker: Mr B. Van Driel (Amsterdam, NL)

Thumbnail

Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysis

Speaker: Doctor A. Masri (Portland, US)

Thumbnail

Access the full session

Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Speakers: Doctor C. Ho, Doctor P. Garcia-Pavia, Doctor C. Coats, Mr B. Van Driel, Doctor A. Masri
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations